Literature DB >> 17324963

Cellular and molecular studies of Marfan syndrome mutations identify co-operative protein folding in the cbEGF12-13 region of fibrillin-1.

Pat Whiteman1, Antony C Willis, Andrew Warner, James Brown, Christina Redfield, Penny A Handford.   

Abstract

Human fibrillin-1 is an extra-cellular matrix glycoprotein with a modular organisation that includes 43 calcium-binding epidermal growth factor-like (cbEGF) domains arranged as multiple tandem repeats interspersed with transforming growth factor beta binding protein-like (TB) domains. We have studied Marfan syndrome-causing mutations which affect calcium binding to cbEGF13, and demonstrate that in human fibroblast cells they cause unexpected endoplasmic reticulum retention, indicative of a folding defect. Biochemical and biophysical studies of in vitro refolded fragments from the TB3-cbEGF14 region indicate long-range and unidirectional effects of these substitutions on the adjacent N-terminal domain cbEGF12. In contrast, only short-range effects of a pathogenic mutation affecting calcium binding to cbEGF19 are observed, and secretion of this mutant protein occurs. Further NMR studies on wild-type cbEGF12-13 and cbEGF12-14 identify a co-operative dependence of domain folding where calcium binding to cbEGF13 is required before cbEGF12 can adopt a native Ca(2+)-dependent fold. These data demonstrate that during biosynthesis of fibrillin-1, multiple tandem repeats of cbEGF domains may not necessarily fold independently and therefore missense mutations resulting in identical substitutions may have different effects on the fate of the mutant protein. Complex folding of modular proteins should therefore be considered when interpreting the molecular pathology of single-gene disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324963     DOI: 10.1093/hmg/ddm035

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  14 in total

1.  Exon 47 skipping of fibrillin-1 leads preferentially to cardiovascular defects in patients with thoracic aortic aneurysms and dissections.

Authors:  Wen-Jing Wang; Peili Han; Jun Zheng; Fang-Yuan Hu; Yun Zhu; Jin-Sheng Xie; Jian Guo; Zhe Zhang; Jie Dong; Gu-Yan Zheng; Huiqing Cao; Tian-Shu Liu; Qinglin Fu; Lizhong Sun; Bi-Bo Yang; Xiao-Li Tian
Journal:  J Mol Med (Berl)       Date:  2012-07-08       Impact factor: 4.599

2.  Allele-specific siRNA knockdown as a personalized treatment strategy for vascular Ehlers-Danlos syndrome in human fibroblasts.

Authors:  Gerd A Müller; Uwe Hansen; Zhi Xu; Benjamin Griswold; Mark I Talan; Nazli B McDonnell; Wilfried Briest
Journal:  FASEB J       Date:  2011-10-28       Impact factor: 5.191

Review 3.  Extracellular matrix: from atomic resolution to ultrastructure.

Authors:  Ioannis Vakonakis; Iain D Campbell
Journal:  Curr Opin Cell Biol       Date:  2007-10-17       Impact factor: 8.382

4.  The clinical spectrum of missense mutations of the first aspartic acid of cbEGF-like domains in fibrillin-1 including a recessive family.

Authors:  Yvonne Hilhorst-Hofstee; Marry E B Rijlaarsdam; Arthur J H A Scholte; Marietta Swart-van den Berg; Michel I M Versteegh; Iris van der Schoot-van Velzen; Hans-Joachim Schäbitz; Emilia K Bijlsma; Marieke J Baars; Wilhelmina S Kerstjens-Frederikse; Jacques C Giltay; Ben C Hamel; Martijn H Breuning; Gerard Pals
Journal:  Hum Mutat       Date:  2010-12       Impact factor: 4.878

5.  Identification of a novel FBN1 gene mutation in a Chinese family with Marfan syndrome.

Authors:  Bo Meng; Hongyi Li; Tao Yang; Shangzhi Huang; Xian Sun; Huiping Yuan
Journal:  Mol Vis       Date:  2011-09-17       Impact factor: 2.367

6.  Identification and study of a FBN1 gene mutation in a Chinese family with ectopia lentis.

Authors:  Hongyi Li; Wei Qu; Bo Meng; Shuihua Zhang; Tao Yang; Shangzhi Huang; Huiping Yuan
Journal:  Mol Vis       Date:  2012-02-24       Impact factor: 2.367

7.  A microfibril assembly assay identifies different mechanisms of dominance underlying Marfan syndrome, stiff skin syndrome and acromelic dysplasias.

Authors:  Sacha A Jensen; Sarah Iqbal; Alicja Bulsiewicz; Penny A Handford
Journal:  Hum Mol Genet       Date:  2015-05-15       Impact factor: 6.150

8.  The First Scube3 Mutant Mouse Line with Pleiotropic Phenotypic Alterations.

Authors:  Helmut Fuchs; Sibylle Sabrautzki; Gerhard K H Przemeck; Stefanie Leuchtenberger; Bettina Lorenz-Depiereux; Lore Becker; Birgit Rathkolb; Marion Horsch; Lillian Garrett; Manuela A Östereicher; Wolfgang Hans; Koichiro Abe; Nobuho Sagawa; Jan Rozman; Ingrid L Vargas-Panesso; Michael Sandholzer; Thomas S Lisse; Thure Adler; Juan Antonio Aguilar-Pimentel; Julia Calzada-Wack; Nicole Ehrhard; Ralf Elvert; Christine Gau; Sabine M Hölter; Katja Micklich; Kristin Moreth; Cornelia Prehn; Oliver Puk; Ildiko Racz; Claudia Stoeger; Alexandra Vernaleken; Dian Michel; Susanne Diener; Thomas Wieland; Jerzy Adamski; Raffi Bekeredjian; Dirk H Busch; John Favor; Jochen Graw; Martin Klingenspor; Christoph Lengger; Holger Maier; Frauke Neff; Markus Ollert; Tobias Stoeger; Ali Önder Yildirim; Tim M Strom; Andreas Zimmer; Eckhard Wolf; Wolfgang Wurst; Thomas Klopstock; Johannes Beckers; Valerie Gailus-Durner; Martin Hrabé de Angelis
Journal:  G3 (Bethesda)       Date:  2016-12-07       Impact factor: 3.154

9.  C-terminal propeptide is required for fibrillin-1 secretion and blocks premature assembly through linkage to domains cbEGF41-43.

Authors:  Sacha A Jensen; Georgia Aspinall; Penny A Handford
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

10.  Structure of the fibrillin-1 N-terminal domains suggests that heparan sulfate regulates the early stages of microfibril assembly.

Authors:  David A Yadin; Ian B Robertson; Joanne McNaught-Davis; Paul Evans; David Stoddart; Penny A Handford; Sacha A Jensen; Christina Redfield
Journal:  Structure       Date:  2013-09-12       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.